Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ACC 2015: Amgen, Regeneron/Sanofi make case for PCSK9 inhibitor safety

This article was originally published in Scrip

Executive Summary

Amgen and its competitor Regeneron Pharmaceuticals with partner Sanofi won't report data from large-scale cardiovascular outcomes studies for their PCSK9 inhibitors until 2017, but the companies are sharing longer-term data from smaller clinical trials for their cholesterol-lowering therapies in hopes of encouraging prescriptions of the injectable drugs following US FDA approval later this year.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts